Let's not forget that the IP associated with our collaborative R&D is ours and that it will be the basis of our OmniCAR platform "extensions".
I'm curious to know if Thermo Fisher intend continuing to use Prescient as a case study into the clinic OR whether we are being strategically positioned within the Cell Therapy Collaboration Center Program in Singapore to accelerate therapy development across Asia Pacific... or better still, both.
Making immunotherapy safer, effective, cheaper and accessible can only be built upon collaboration. PTX's programs (to date) are proving to be safe and efficacious, and with our partnership with TF, it could have the technology and access to the equipment to make them cheaper and accessible.
Bring on the newsflow!
Announcement, page-5
Add PTX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
4.3¢ |
Change
-0.001(2.27%) |
Mkt cap ! $34.62M | |||
| Open | High | Low | Value | Volume |
| 4.3¢ | 4.5¢ | 4.3¢ | $17.99K | 416.9K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 152502 | 4.3¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 4.5¢ | 502504 | 5 |
View Market Depth
| Last trade - 15.59pm 17/05/2024 (20 minute delay) ? |
|
|||||
|
Last
4.3¢ |
Change
-0.001 ( 4.44 %) |
||||
| Open | High | Low | Volume | ||
| 4.3¢ | 4.5¢ | 4.3¢ | 123400 | ||
| Last updated 15.57pm 17/05/2024 ? | |||||
| PTX (ASX) Chart |